CEO / Co-founder
Lactiga
Lactiga is developing novel biologics derived from human milk to create antibodies that target mucosal infections in patients with Primary Immunodeficiency Diseases. This approach addresses the high risk of recurrent infections and complications faced by these vulnerable patients, offering a potential improvement in their quality of life.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$1.3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Patients with Primary Immunodeficiency Diseases (PIDD) face a high risk of recurrent mucosal infections, such as respiratory and gastrointestinal infections, leading to complications and frequent hospitalizations. Current treatment options are costly and may not effectively prevent infections at the point of entry.
Solution
Lactiga is developing novel biologics derived from human milk to create secretory IgA (sIgA) antibodies that target mucosal infections, offering a new approach to prevent and treat infections in patients with PIDD. The company's first-in-class sIgA therapeutic has the potential to enhance mucosal immunity across conditions affecting the respiratory, digestive, and ocular compartments. Lactiga's patented technology harnesses maternal antibodies naturally found in breastmilk to develop anti-infectives that can battle even the world’s most dangerous pathogens. This approach aims to improve the quality of life for immunocompromised patients by providing more effective therapies that prevent infection at the point of entry.
Target Audience
The primary target audience includes patients with Primary Immunodeficiency Diseases (PIDD) and other immunocompromised individuals at high risk of mucosal infections, as well as healthcare providers specializing in immunology and infectious diseases.
Features
- Novel biologics derived from human milk
- Secretory IgA (sIgA) antibody platform
- Mucosal-targeted therapeutics for respiratory, digestive, and ocular infections
- Patented technology for developing anti-infectives
- Collaboration with Kenox Pharmaceuticals for innovative delivery technologies